Gingivitis Pathogenesis Involves Upregulation of Glycolysis and Citric Acid Cycle Activity Mediated by Bacterial Virulence Factors
International Journal of Molecular Sciences · 12.06.2026 · 27 (12) · 5316
DOI: 10.3390/ijms27125316 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.06.2026. Verfasst von Sancai Xie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Corporate Functions R&D, The Procter & Gamble Company, Mason, OH 45040, USA. Hauptthemen laut MEDLINE: Virulence Factors, Glycolysis, Gingivitis, Citric Acid Cycle. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Procter & Gamble (United States), Procter & Gamble Company.
Abstract (Originalsprache)
This research analyzed metabolomic and proteomic differences between participants with gingivitis (>20 bleeding sites) and generally healthy participants (≤3 bleeding sites) at baseline and 4 weeks post stannous fluoride (SnF2) dentifrice treatment. Sixty-two metabolites were different (p < 0.05) between groups at baseline. Forty cytokines were analyzed using immunoassays and a group of proinflammatory cytokines (IL-1α, IL-1β, TNF-α, SAA, ICAM-1, VCAM-1) was elevated in participants with gingivitis (p < 0.1) versus healthy gingiva at baseline, with C-reactive protein (p < 0.05) being significantly elevated. Proteomic analysis carried out in baseline oral lavage revealed four of the top hits (p < 0.0004) were central-metabolism-related: aldolase A, triosephosphate isomerase, lactate dehydrogenase, and malate dehydrogenase. Enzymatic assays confirmed the proteomic finding that malate dehydrogenase and triosephosphate isomerase activities were elevated in gingivitis samples; SnF2 dentifrice treatment reduced their activity. Collectively, 20 proteins with the lowest p-values in oral lavage appeared to be indicative of periodontal health, potentially forming the basis to cluster samples into healthy and unhealthy groups. A TLR-ATP biosensor model was established and demonstrated that microbial virulence factors induced the observed changes in oral lavage. Combined findings suggest gingivitis involves upregulation of host cell bioenergetic processes involving enzymatic activity in the glycolysis and citric acid cycle pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Corporate Functions R&D, The Procter & Gamble Company, Mason, OH 45040, USA.
- Global Oral Care R&D, The Procter & Gamble Company, Mason, OH 45040, USA.
- Global Baby, Feminine, Family Care Life Sciences, The Procter & Gamble Company, Cincinnati, OH 45224, USA.
ORCID-Profile: Sancai Xie, Tom Huggins, Lijuan Li
Förderung
- Procter & Gamble (United States)
- Procter & Gamble Company
Zitieren
APA
Xie, S., Klukowska, M., Wang, J., Huggins, T., Ashe, J., Tansky, C. S., Li, L., Circello, B., Ramji, N., White, D. J., & Biesbrock, A. R. (2026). Gingivitis Pathogenesis Involves Upregulation of Glycolysis and Citric Acid Cycle Activity Mediated by Bacterial Virulence Factors. International Journal of Molecular Sciences, 27(12), 5316. https://doi.org/10.3390/ijms27125316
Vancouver
Xie S, Klukowska M, Wang J, Huggins T, Ashe J, Tansky CS, et al. Gingivitis Pathogenesis Involves Upregulation of Glycolysis and Citric Acid Cycle Activity Mediated by Bacterial Virulence Factors. International Journal of Molecular Sciences. 2026;27(12):5316. doi:10.3390/ijms27125316
BibTeX
@article{Xie2026,
author = {Xie, Sancai and Klukowska, Malgorzata and Wang, Jiazhen and Huggins, Tom and Ashe, Julie and Tansky, Cheryl S and Li, Lijuan and Circello, Benjamin and Ramji, Niranjan and White, Donald J and Biesbrock, Aaron R},
title = {Gingivitis Pathogenesis Involves Upregulation of Glycolysis and Citric Acid Cycle Activity Mediated by Bacterial Virulence Factors},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5316},
doi = {10.3390/ijms27125316}
}
EUVIMED